Helsinn Therapeutics (U.S.), Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$3.7M
Doctors Paid
5,927
Transactions
12,778
2024 Total
$24,293
Payment Breakdown by Category
Research$1.7M (47.0%)
Consulting$642,270 (17.5%)
Food & Beverage$238,047 (6.5%)
Travel$149,269 (4.1%)
Royalty/License$61,199 (1.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.7M | 56 | 47.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $750,970 | 308 | 20.5% |
| Consulting Fee | $642,270 | 97 | 17.5% |
| Food and Beverage | $238,047 | 11,678 | 6.5% |
| Travel and Lodging | $149,269 | 462 | 4.1% |
| Space rental or facility fees (teaching hospital only) | $77,745 | 46 | 2.1% |
| Royalty or License | $61,199 | 13 | 1.7% |
| Grant | $20,000 | 2 | 0.5% |
| Education | $1,610 | 116 | 0.0% |
Payments by Type
General
$1.9M
12,722 transactions
Research
$1.7M
56 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| Valchor Therapy in Conjunction with Triamcinolone 0.1 Ointment for the Treatment of Contact Dermatitis in Subjects with Early Stage Cutaneous T-cell Lymphoma | $493,298 | 0 | 9 |
| Treatment of Refractory Nausea | $472,355 | 0 | 13 |
| Prevention of CINV in patients receiving MEC/HEC who experienced breakthrough after one cycle of chemotherapy | $255,375 | 0 | 8 |
| Valchlor Therapy in Conjunction with Triamcinolone 0.1% Ointment for the Treatment of Contact Dermatitis in Subjects with Early Stage Cutaneous T-cell Lymphoma | $124,432 | 0 | 1 |
| Trial of NEPA for Prevention of CINV in Patients receiving the BEAM | $104,032 | 0 | 7 |
| Trial of NEPA for Prevention of CINV in Patients receiving BEAM | $89,101 | 0 | 5 |
| Valchlor In The Treatment Of Lichen Planopilaris A Single Arm, Open-Label, Exploratory Study | $51,433 | 0 | 3 |
| Trial for NEPA for Prevention of CINV in Patients receiving BEAM | $46,504 | 0 | 3 |
| A single centered Retrospective Study of Topical Mechlorethamine Treatment Outcomes in Patients with Mycosis Fungoides | $25,000 | 0 | 2 |
| : Valchlor In The Treatment Of Lichen Planopilaris: A Single Arm, Open-Label, Exploratory Study | $22,500 | 0 | 1 |
| Evaluating the Efficacy of Akynzeo in the management of CINV in patients treated for advanced stage ovarian carcinoma | $19,635 | 0 | 2 |
| Single-Center, Single-Arm, Open-Label feasibility study | $18,963 | 0 | 2 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2023 |
|---|---|---|---|---|
| Philip Schein, M.d, M.D | Medical Oncology | Bryn Mawr, PA | $275,678 | $0 |
| Brian Poligone, Md, MD | Dermatology | Fairport, NY | $96,337 | $0 |
| Dr. Mack Rachal, M.d, M.D | Dermatology | Atlanta, GA | $88,288 | $0 |
| Dr. May Cho, M.d, M.D | Internal Medicine | Orange, CA | $63,432 | $0 |
| Dr. Nitin Rohatgi, M.d, M.D | Hematology | Sacramento, CA | $55,055 | $0 |
| Theresa Pacheco, Md, MD | Procedural Dermatology | Aurora, CO | $52,688 | $0 |
| Dr. Larisa Geskin, Md, MD | Dermatology | New York, NY | $38,792 | $0 |
| William Hamilton, Md, MD | Anatomic Pathology & Clinical Pathology | Gainesville, FL | $34,555 | $0 |
| Dr. Donald Boyd, M.d, M.D | Hematology & Oncology | Greenwich, CT | $33,585 | $0 |
| Lindsay Ackerman, Md, MD | Dermatology | Phoenix, AZ | $32,194 | $0 |
| Dr. Suresh Ratnam, Md, MD | Medical Oncology | Mcallen, TX | $31,805 | $0 |
| Dr. Tobenna Nwizu, M.d, M.D | Internal Medicine | Rowlett, TX | $30,909 | $0 |
| Devesh Pandya, M.d, M.D | Hematology & Oncology | Houston, TX | $29,750 | $0 |
| Dr. Oleg Akilov, M.d., Ph.d, M.D., PH.D | Dermatology | Pittsburgh, PA | $26,546 | $0 |
| Dr. Jennifer Desimone, Md, MD | Dermatology | Fairfax, VA | $25,769 | $0 |
| Allison Goddard, Md, MD | Dermatology | Falmouth, ME | $25,002 | $0 |
| Dr. Dialecti Voudouris | Specialist | New York, NY | $23,246 | $0 |
| Paul Oberstein, Md, MD | Internal Medicine | New York, NY | $22,893 | $0 |
| Dr. Afsaneh Barzi, M.d, M.D | Internal Medicine | Los Angeles, CA | $21,072 | $0 |
| Dr. Camille Introcaso, Md, MD | Dermatology | Marlton, NJ | $20,766 | $0 |
| Charles Camisa, M.d, M.D | Dermatology | Ft. Myers, FL | $19,861 | $0 |
| Dr. Cory Rubin, M.d, M.D | Clinical & Laboratory Dermatological Immunology | Waterford, MI | $18,555 | $0 |
| Dr. Lucia Seminario Vidal, M.d.,Ph.d, M.D.,PH.D | Dermatology | Tampa, FL | $18,287 | $0 |
| Stephanie Fabbro, M.d, M.D | Dermatology | Columbus, OH | $17,900 | $0 |
| Lee Schwartzberg, Md, MD | Hematology | Reno, NV | $17,480 | $0 |
About Helsinn Therapeutics (U.S.), Inc.
Helsinn Therapeutics (U.S.), Inc. has made $3.7M in payments to 5,927 healthcare providers, recorded across 12,778 transactions in the CMS Open Payments database. In 2024, the company paid $24,293. The top product by payment volume is VALCHLOR ($1.6M).
Payments were distributed across 99 medical specialties. The top specialty by payment amount is Dermatology ($664,994 to 1,459 doctors).
Payment categories include: Food & Beverage ($238,047), Consulting ($642,270), Research ($1.7M), Travel & Lodging ($149,269), Royalties ($61,199).
Helsinn Therapeutics (U.S.), Inc. is associated with 1 products in the CMS Open Payments database.